InvestorsHub Logo
Followers 828
Posts 119585
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 12/23/2019 3:23:55 PM

Monday, December 23, 2019 3:23:55 PM

Post# of 209
FDA approves AGN’s Ubrelvy (ubrogepant) for acute migraine treatment:

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine

Ubrelvy may do well in the crowded CGRP arena because it’s oral.

AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.

AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”